After institutional review board approval, a review was performed of the records of all patients examined and treated at the University of MiamiWound Clinic, Miami, during a 2-year period (December 1, 1998–December 1, 2000). All patients included met the clinicopathological criteria for lowerextremity PG. These include clinical criteria (painful ulceration, an undermined border, surrounding erythema, a purulent base, and rapid onset and enlargement)and histologic criteria (epidermal necrosis/ulceration, superficial dermal edema, and a dense, neutrophilic, and mixed dermal/subcutaneous infiltrate).Patients had noninfectious chronic ulcerations clinically typical for PG and the exclusion of relevant differential diagnoses through biopsy, tissue culture,and appropriate laboratory studies. If a patient had multiple ulcers, the target lesion was defined as the largest ulcer. Treatment measures other thanprednisone included cyclosporine, intralesional triamcinolone acetonide, minocycline, doxycycline, granulocyte-macrophage colony-stimulating factor, oral tacrolimus,and colchicine (Table 1). Outcomes compared between patients with PG and those with PGA included complete healing,percentage change in wound size, and duration of therapy. Arthritis was defined as one or more of the following findings: rheumatoid factor positive, physicalfindings of arthritis, or arthritis by medical history. Percentage change in wound size was defined as follows: (ulcer sizeb − ulcer sizef)/(sizeb × 100). In the equation, b is baseline; and f, final. Statistical methodsincluded paired t tests and the signed rank test.